Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.53 |
| ▸ | CFTR | P13569 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 8/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | PKLR | P30613 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1340573 | 0.80 | ALDH1A1 (0.66) | ALDH1A1HSD17B10CFTRMAPTPOLB | |
| SCHEMBL21291406 | 0.80 | MAPT (0.48) | ALDH1A1HSD17B10CFTRMAPTPOLB | |
| SCHEMBL7119473 | 0.80 | ALDH1A1 (0.53) | ALDH1A1HSD17B10CFTRMAPTPOLB | |
| SCHEMBL5887723 | 0.80 | SIRT1 (0.61) | ALDH1A1HSD17B10CFTRMAPTPOLB | |
| SCHEMBL4440485 | 0.79 | HSD17B10 (0.64) | ALDH1A1HSD17B10CFTRMAPTPOLB | |
| SCHEMBL14176672 | 0.79 | MAPT (0.56) | ALDH1A1HSD17B10CFTRMAPTPOLB | |
| SCHEMBL6934406 | 0.79 | HSD17B10 (0.53) | ALDH1A1HSD17B10CFTRMAPTPOLB | |
| SCHEMBL6934243 | 0.78 | SMN1; SMN2 (0.50) | ALDH1A1HSD17B10CFTRMAPTPOLB | |
| SCHEMBL7620547 | 0.78 | ALDH1A1 (0.50) | ALDH1A1HSD17B10CFTRMAPTPOLB | |
| SCHEMBL7754027 | 0.78 | HSD17B10 (0.62) | ALDH1A1HSD17B10CFTRMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875727-B2 | methyl [5(6)-(4-alanylaminophenylthio)-1H-benzimidazol-2yl]carbamate; for treating neovascularization, solid tumors, macular degeneration, diabetic retinopathy, rheumatoid arthritis, psoriasis, and atherosclerosis | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2011-01-25 | — | — | US | disclosed |
| EP-1140078-B1 | BENZIMIDAZOLE VASCULAR DAMAGING AGENTS | ANGIOGENE PHARM LTD (GB) | 2007-08-29 | — | — | EP | disclosed |
| US-20060264492-A1 | Benzimidazole vascular damaging agents | ANGIOGENE PHARMACEUTICALS LTD. | 2006-11-23 | — | — | US | disclosed |
| US-7081469-B2 | Benzimidazole vascular damaging agents | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2006-07-25 | — | — | US | disclosed |
| US-20040058972-A1 | Benzimidazole vascular damaging agents | DAVIS PETER DAVID (GB) | 2004-03-25 | — | — | US | disclosed |
| US-6645950-B1 | Benzimidazole-2-carbamates; antitumor agents; angiogenesis inhibitors; macular degeneration, diabetic retinopathy, rheumatic arthritis, psoriasis, and atherosclerosis treatment | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2003-11-11 | — | — | US | disclosed |
| EP-1140078-A2 | BENZIMIDAZOLE VASCULAR DAMAGING AGENTS | Angiogene Pharmaceuticals Ltd (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000041669-A2 | BENZIMIDAZOLE VASCULAR DAMAGING AGENTS | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058972-A1 | Benzimidazole vascular damaging agents | FLT1, FLT4, PCNA | ALDH1A1 204/4885HSD17B10 3732/4885CFTR 3155/4885 |
| US-20060264492-A1 | Benzimidazole vascular damaging agents | FLT4, PCNA, FLT1 | ALDH1A1 381/4885HSD17B10 3890/4885CFTR 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.